Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
|Articles|October 2, 2016
- Pharmaceutical Technology-10-02-2016
- Volume 40
- Issue 10
Double Planetary Mixers for Heavy Duty Mixing
The Double Planetary Mixers from Ross, Charles & Son are offered in 4-, 5-, 10-, and 25-gallon models for pilot-scale production of highly-filled pastes, dough-like materials, shear-sensitive gels, granulations, and powder blends.
The Double Planetary Mixers from Ross, Charles & Son are offered in 4-, 5-, 10-, and 25-gallon models for pilot-scale production of highly-filled pastes, dough-like materials, shear-sensitive gels, granulations, and powder blends. These mixers are also used for vacuum drying of heat-sensitive applications at relatively low temperatures. The blades are ideal for heavy-duty mixing of viscous materials up to six million centipoise, and the helical curve and graduated down-thrust cross-section of the high viscosity blades prevent product from climbing up into the cover. The mixers vacuum capability allows users to remove air from the batch before starting the agitators or during the mixing cycle, which results in a smooth void-free finished product without the need for additional defoaming or deaeration post-mixing.
Articles in this issue
almost 10 years ago
Ophthalmic Drug Packaging: Safety Risks and Patient Acceptability Issuesalmost 10 years ago
Improving Feeder Performance in Continuous Pharmaceutical Operationsalmost 10 years ago
Protecting Parenterals in Primary Packagingalmost 10 years ago
Manufacturers Face Major Changes under PDUFA VIalmost 10 years ago
Defining Risk Assessment of Aseptic Processesalmost 10 years ago
Fill/Finish Outsourcingalmost 10 years ago
Calling All Authorsalmost 10 years ago
Excipients for Formulation Successalmost 10 years ago
Tracking a Global ProblemRelated to this article
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.